SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amidst intense community debate following former President Trump's proposal to impose tariffs on European nations unless Greenland is ceded to the United States. Supporters tout this as a strategic move for national security and Arctic dominance, while critics express concern over potential market instability, diplomatic fallout with NATO allies, and broader geopolitical tensions. The discussions highlight significant divisions regarding trade policy and international relations.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's new tariff threats against several European nations, linked to a demand for Greenland, have sparked significant market concern. The community is sharply divided, with many predicting a substantial downturn due to escalating trade tensions and fears of a critical shift in global alliances, while others anticipate the market will largely absorb the news, citing a persistent "buy the dip" mentality. As a tech-heavy index, QQQ faces scrutiny over how these geopolitical risks will impact a highly valued market environment amid looming retaliatory measures from Europe.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending due to forecasts of an intensifying and widespread cold snap across the US, potentially extending into February. This has sparked widespread community discussion about a significant short squeeze, given the commodity's high short interest and anticipated heating demand, alongside concerns about the inherent volatility and decay of leveraged natural gas products.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending due to the recent Saudi FDA approval of its Anktiva therapy for lung and bladder cancer, a move widely seen as a significant global validation for its "chemo-free" approach. The community is buzzing with optimism about the potential paradigm shift in oncology and is anticipating a substantial short squeeze, fueled by high short interest and continuous active engagement from the company's chairman on social media regarding ongoing regulatory discussions. Investors are closely monitoring for further updates from leadership and potential partnerships, expecting a re-evaluation of the company's market position.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance (AERO) is a central talking point as its pivotal role as the liquidity hub for the growing Base ecosystem gains traction, bolstered by its recent listing on Robinhood and a strategic merger with Velodrome. Community members are actively debating its potential as the "Uniswap of this cycle," citing strong fundamentals like revenue surpassing emissions and anticipating significant future growth, despite navigating current market volatility. The ongoing discussions around regulatory clarity further underscore AERO's position within the evolving DeFi landscape.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is generating significant conversation following its recent quantum computing breakthroughs, including new processors aimed at achieving quantum advantage by 2026 and fault-tolerant computing by 2029. This, coupled with its strategic push into enterprise AI through initiatives like the reported acquisition of Confluent for enhanced data streaming, is driving community optimism. Analysts increasingly view IBM as an undervalued, low-risk play with strong potential in hybrid cloud, AI consulting, and its evolving quantum ecosystem.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to renewed geopolitical tensions stemming from tariff threats against European countries over Greenland, which has triggered an immediate sell-off in futures markets while safe-haven assets like gold and silver surge. The community is bracing for significant volatility and discussing potential market corrections, with some anticipating a 'TACO Tuesday' recovery contrasting with widespread fears of a deeper downturn.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Ethereum is a major talking point as its anticipated Fusaka Upgrade nears, promising enhanced network efficiency that fuels bullish sentiment. Community discussions emphasize growing institutional interest and asset tokenization, affirming Ethereum's foundational role in the evolving digital finance ecosystem.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as the community reacts to a notable exchange decision reversal and an upcoming network upgrade, alongside the highly anticipated sentencing hearing for Do Kwon. Investors are actively discussing significant burn mechanisms and various ecosystem developments like LUNCVERSE, fueling optimism for LUNC's long-term revival within a broader bullish sentiment for altcoins.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is seeing a strong surge, fueled by positive business updates, including an improved financial outlook and significant progress in its flu vaccine and oncology pipeline. This comes as a favorable European patent ruling reduces legal concerns, sparking community discussion about a potential short squeeze given the substantial short interest and perceived undervaluation compared to its long-term therapeutic potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field.”</li><li>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.&nbsp;</li><li>BioNTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies.</li></ul>Shares of BioNTech SE (BNTX) rose 3% on Friday after Goldman Sachs upgraded the stock to ‘Buy’ from ‘Neutral’.Goldman also raised the price target on the stock to $142, up from $115, according to TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Thursday. &nbsp;<h2 class="st-heading-2">Goldman’s Rationale</h2>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field” and uniquely positioned to develop novel combination approaches to transform cancer care.Data unlocks in 2026 could position the company with “a leading foothold in an emerging wave of new product cycles,” the analyst added.<h2 class="st-heading-2">Pipeline</h2>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.BionTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. It is also developing several combination approaches.In 2026, the company expects seven late-stage data readouts, and also looks forward to applying to the U.S. Food and Drug Administration (FDA) for approval of its drug T-Pam in endometrial cancer. BioNTech hopes to become a multi-product oncology company by 2030.The company, however, does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BNTX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user, however, highlighted concerns with the company’s recent acquisition of CureVac. BioNTech closed the acquisition of CureVac in December after<a href="https://stocktwits.com/news-articles/markets/equity/biontech-to-acquire-curevac-in-all-stock-deal-valued-at-1.25-billion/chlXz8nRb6u"> announcing </a>the all-stock deal in June to support its oncology strategy.<stembedurl>https://www.stocktwits.com/taxplanr/message/642106083</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> has fallen 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/genmab-reports-mixed-results-from-late-stage-trial-of-lymphoma-drug/cmUmGfeR4Bt">Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio

Goldman raised the price target on BioNTech SE to $142, up from $115.

Equity

SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX

SG Americas Securities LLC lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 77.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The...

BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the firm, Marketbeat.com...

<ul class="summary-bullets"><li>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.</li><li>Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out.</li><li>Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response.</li></ul>Genmab A/S (GMAB) on Monday said that it will discontinue further clinical development of Acasunlimab as part of its efforts to focus on the most value-creating areas.The clinical profile observed of Acasunlimab has been encouraging to date, but the company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.genmab.com/news-releases/news-release-details/genmab-portfolio-prioritization-update">said.</a> &nbsp;“Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina‑S, and we remain committed to executing these programs with speed and rigor,” said Genmab CEO Jan van de Winkel.NASDAQ-listed shares of the company fell 2% at the time of writing.<h2 class="st-heading-2">Collaboration With BioNTech</h2>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.The discontinued drug was developed by Copenhagen based Genmab with Germany based BioNTech. Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out citing reasons relating to its portfolio strategy.Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response. It was being studied in multiple trials including one in patients with non-small cell lung cancer (NSCLC).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GMAB stayed within the ‘bullish’ territory accompanied by ‘low’ message volume while sentiment around <a href="https://stocktwits.com/symbol/BNTX">BNTX</a> stayed within ‘neutral’ territory with ‘normal’ levels of retail chatter.<a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 57% this year and by about 58% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech

The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 

BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd.

TB Alternative Assets Ltd. lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 92.7% in the 3rd quarter, according to the company in its most recent 13F filing...

Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX

Vontobel Holding Ltd. boosted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 17.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX

Hudson Bay Capital Management LP cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 9.1% in the second quarter, according to the company in its most recent filing with the...

FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of BioNTech in a research note issued to investors on Wednesday...

Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX

Gilder Gagnon Howe & Co. LLC grew its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTXBioNTech SE - ADR